Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Interest Coverage Ratio (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Interest Coverage Ratio over the past 12 years, most recently at 37.4 for Q4 2025.

  • Quarterly results put Interest Coverage Ratio at 37.4 for Q4 2025, up 77.89% from a year ago — trailing twelve months through Dec 2025 was 73.53 (up 45.17% YoY), and the annual figure for FY2025 was 73.44, up 46.04%.
  • Interest Coverage Ratio for Q4 2025 was 37.4 at Viridian Therapeutics, Inc.\DE, up from 71.45 in the prior quarter.
  • Over the last five years, Interest Coverage Ratio for VRDN hit a ceiling of 37.4 in Q4 2025 and a floor of 9693.67 in Q4 2021.
  • Median Interest Coverage Ratio over the past 5 years was 173.94 (2023), compared with a mean of 777.47.
  • Biggest five-year swings in Interest Coverage Ratio: plummeted 1825.94% in 2021 and later surged 96.99% in 2022.
  • Viridian Therapeutics, Inc.\DE's Interest Coverage Ratio stood at 9693.67 in 2021, then surged by 96.99% to 292.06 in 2022, then skyrocketed by 38.82% to 178.7 in 2023, then grew by 5.32% to 169.19 in 2024, then soared by 77.89% to 37.4 in 2025.
  • The last three reported values for Interest Coverage Ratio were 37.4 (Q4 2025), 71.45 (Q3 2025), and 207.72 (Q2 2025) per Business Quant data.